Table 1.
Demographic and Clinical Characteristics at Baselinea
| Total N=62 |
Oxytocin N=32 |
Placebo N=30 |
|
|---|---|---|---|
| Age, years | 39.1 ± 12.5 | 41.9 ± 12.2 | 36.1 ± 12.3 |
| Gender, male, N (%) | 47 (75.8) | 24 (75.0) | 23 (76.7) |
| Race, N (%) | |||
| White | 31 (50.0) | 15 (46.9) | 16 (53.3) |
| Black | 26 (41.9) | 14 (43.8) | 12 (40.0) |
| Other | 5 (8.1) | 3 (9.3) | 2 (6.7) |
| Schizophrenia, N (%) | 39 (62.3) | 19 (59.4) | 20 (65.5) |
| Schizoaffective disorder, N (%) | 23 (37.7) | 13 (40.6) | 10 (34.5) |
| CGI-S | 4.0 ± 0.6 | 4.0 ± 0.7 | 3.9 ± 0.6 |
| PANSS total | 67.3 ± 12.2 | 65.8 ± 12.8 | 69.0 ± 11.5 |
| PANSS positive | 16.9 ± 4.9 | 16.6 ± 4.8 | 17.3 ± 5.0 |
| PANSS negative | 17.9 ± 4.6 | 17.4 ± 4.6 | 18.5 ± 4.7 |
| PANSS general psychopathology | 32.5 ± 6.4 | 31.8 ± 6.7 | 33.2 ± 6.1 |
| WRAT word reading standard score | 95.8 ± 14.4 | 93.6 ± 14.7 | 98.4 ± 14.0 |
| Concomitant medications, N (%) | |||
| Antipsychotics | 59 (95.1) | 30 (93.8) | 29 (96.7) |
| First-generation antipsychotics | 8 (12.9) | 4 (12.5) | 4 (13.3) |
| Second-generation antipsychotics | 53 (85.4) | 27 (84.3) | 26 (86.7) |
| Antidepressants | 25 (40.3) | 15 (46.8) | 10 (33.3) |
| Mood stabilizers | 17 (27.4) | 12 (37.5) | 5 (16.6) |
| Benzodiazepines | 15 (24.1) | 6 (18.7) | 9 (30.0) |
Abbreviations: CGI-S, Clinical Global Impressions-Severity scale; PANSS, Positive and Negative Syndrome Scale; WRAT, Wide Range Achievement Test
a
Data presented as mean ± standard deviation, unless otherwise indicated.